logo
#

Latest news with #OVID

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Yahoo

time13-05-2025

  • Business
  • Yahoo

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.14 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced a loss of $0.13, delivering a surprise of 18.75%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Ovid Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.13 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 96.97%. This compares to year-ago revenues of $0.15 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Ovid Therapeutics shares have lost about 67.7% since the beginning of the year versus the S&P 500's decline of -0.6%. While Ovid Therapeutics has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Ovid Therapeutics: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.14 on $0.09 million in revenues for the coming quarter and -$0.57 on $0.38 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, CureVac N.V. (CVAC), is yet to report results for the quarter ended March 2025. This company is expected to post quarterly loss of $0.16 per share in its upcoming report, which represents a year-over-year change of +52.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. CureVac N.V.'s revenues are expected to be $14.47 million, up 7.7% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ovid Therapeutics (OVID) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Yahoo

time02-04-2025

  • Business
  • Yahoo

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 days. About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that have the potential to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit Investor Relations:Victoria Fort 202-361-445 vfort@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store